7T MRS in Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01237210|
Recruitment Status : Recruiting
First Posted : November 9, 2010
Last Update Posted : February 12, 2018
This study is looking for healthy controls and patients with Parkinson's (PD) to perform an MR scan.
- The neurochemical profile of the SN of patients with PD as measured by high field MRS will differ from that of healthy controls, in that glutathione will be lower due to oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis markers myo-inositol and glutamine will be higher due to inflammation (glial activation) and N-acetylaspartate and glutamate will be lower due to neuronal loss/damage.
- There will be a relationship between neurochemical changes and disease severity.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||26 participants|
|Official Title:||Magnetic Resonance Spectroscopy of Parkinson's Disease at 7 Tesla|
|Study Start Date :||February 2010|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||January 2020|
- Magnetic resonance spectroscopy (MRS) [ Time Frame: Baseline ]We will utilize optimized magnetic resonance spectroscopy (MRS) methodology to address theories of pathogenesis of Parkinson's disease (PD) by quantifying glutathione (GSH), lactate, glutamine and myo-inositol levels of the unilateral substantia nigra (SN) of healthy volunteers and patients with PD.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01237210
|United States, Minnesota|
|University of Minnesota/CMRR||Recruiting|
|Minneapolis, Minnesota, United States, 55414|
|Contact: Lisa Coles 612-624-1861 firstname.lastname@example.org|
|Principal Investigator:||Paul Tuite, MD||University of Minnesota - Clinical and Translational Science Institute|